Investment Grants, Data Presentations, Clinical Study Results, and Collaborative Programs - Analyst Notes on UnitedHealth Group,

      Investment Grants, Data Presentations, Clinical Study Results, and
 Collaborative Programs - Analyst Notes on UnitedHealth Group, Bristol-Myers
                      Squibb, AbbVie, Cigna, and OXiGENE

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 14, 2014

NEW YORK, March 14, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding UnitedHealth
Group Incorporated (NYSE: UNH), Bristol-Myers Squibb Company (NYSE: BMY),
AbbVie Inc. (NYSE: ABBV), Cigna Corporation (NYSE: CI), and OXiGENE, Inc.
(NASDAQ: OXGN). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings are
available at: http://www.AnalystsReview.com/register

--

UnitedHealth Group Incorporated Analyst Notes

On March 11, 2014, UnitedHealth Group Incorporated (UnitedHealth Group)
announced that its UnitedHealthcare business has provided a $1.0 million grant
for the Connecticut Children's Medical Center's Office for Community Child
Health (OCCH) to help improve care delivery and address critical public health
issues for children. UnitedHealthcare expects the grant to help create a
Maintenance of Certification program to train primary care paediatricians in
managing diseases. "We are proud to partner with UnitedHealthcare to support
pediatricians' lifelong learning and professional development," said Paul
Dworkin, M.D., Director of OCCH. "Together, we will enhance the quality and
capacity of pediatric care to address an array of critical health issues, and
help promote the healthy development of children in Connecticut and
nationwide." The full analyst notes on UnitedHealth Group Incorporated are
available to download free of charge at:

http://www.AnalystsReview.com/03142014/UNH/report.pdf

--

Bristol-Myers Squibb Company Analyst Notes

On March 5, 2014, Bristol-Myers Squibb Company (Bristol-Myers Squibb)
presented 24-week Phase IIb data that demonstrated similar response rates for
its investigational compound, BMS-663068, when compared to a boosted protease
inhibitor, Reyataz with ritonavir. According to the Company, the study, which
was presented at the 21^st Conference on Retroviruses and Opportunistic
Infections (CROI), highlights the unique mechanism of action of the
investigational prodrug BMS-663068, which when converted into BMS-626529, a
novel attachment inhibitor, prevents initial viral attachment to the host CD4+
T cell and entry into the host immune cell. "These study results are
encouraging and support further development of BMS-663068 as we continue to
look for ways to treat people living with HIV, especially those who have
exhausted available therapies and are difficult to treat," said Douglas
Manion, M.D., Senior Vice President of Development, Virology at Bristol-Myers
Squibb. The full analyst notes on Bristol-Myers Squibb Company are available
to download free of charge at:

http://www.AnalystsReview.com/03142014/BMY/report.pdf

--

AbbVie Inc. Analyst Notes

On March 3, 2014, AbbVie Inc. (AbbVie) presented the first detailed results of
its pivotal phase III study, PEARL-III, at the 21^st Conference on
Retroviruses and Opportunistic Infections (CROI). The Company informed that
PEARL-III evaluated the efficacy and safety of 12 weeks of treatment with
AbbVie's investigational therapy with or without ribavirin (RBV) in
non-cirrhotic, adult patients with chronic genotype 1b (GT1b) hepatitis C
virus (HCV) infection who were new to treatment. The results revealed that
PEARL-III was able to meet its primary and secondary endpoints. "We are
excited about the strong PEARL-III results which demonstrate the AbbVie
regimen achieved high SVR rates with no discontinuations due to adverse events
in patients new to treatment with genotype 1b infection," said Scott Brun,
M.D., Vice President of Pharmaceutical Development at AbbVie. "Additionally,
with these data, we continue to be on track to begin major regulatory
submissions in the second quarter of 2014. AbbVie will continue to disclose
additional detailed phase III study results at future scientific congresses
and in publications." The full analyst notes on AbbVie Inc. are available to
download free of charge at:

http://www.AnalystsReview.com/03142014/ABBV/report.pdf

--

Cigna Corporation Analyst Notes

On March 3, 2014, Cigna Corporation (Cigna) and the Baton Rouge Clinic
announced that they have launched a collaborative accountable care initiative,
which aims to improve patient access to health care, enhance care
coordination, and achieve the "triple aim" of improved health, affordability,
and patient experience. Under the program, the Baton Rouge Clinic will monitor
and coordinate all aspects of an individual's medical care. "We look forward
to expanding our collaborative accountable care program across Louisiana with
the addition of the Baton Rouge Clinic," said Mark Netoskie, M.D., Senior
Medical Director for Louisiana at Cigna. "Our goal is to create a health care
system focused on providing quality care for the patient, which will
ultimately lead to a healthier population and lower medical costs." The full
analyst notes on Cigna Corporation are available to download free of charge
at:

http://www.AnalystsReview.com/03142014/CI/report.pdf

--

OXiGENE, Inc. Analyst Notes

On March 11, 2014, OXiGENE, Inc. (OXiGENE) announced positive results from a
randomized Phase 2 clinical trial evaluating Avastin (bevacizumab) with or
without ZYBRESTAT (fosbretabulin; CA4P) to treat patients with recurrent
ovarian cancer. OXiGENE stated that the study has met its primary endpoint of
a statistically significant increase in progression-free survival for the
combination, as compared to bevacizumab alone. "ZYBRESTAT is the first
vascular disrupting agent to show a statistically significant progression-free
survival benefit, and we are evaluating next steps to advance this combination
to patients in need," said Peter Langecker, M.D., Ph.D., CEO of OXiGENE. The
full analyst notes on OXiGENE, Inc. are available to download free of charge
at:

http://www.AnalystsReview.com/03142014/OXGN/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES:

  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
    AnalystsReview.com.
  oFor any urgent concerns or inquiries, please contact us at compliance [at]
    AnalystsReview.com.
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at]
    AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsReview.com

SOURCE Analysts Review

Contact: Adam Redford, +852-8191-3972
 
Press spacebar to pause and continue. Press esc to stop.